Literature DB >> 26535510

New Math on Drug Cost-Effectiveness.

Peter B Bach1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26535510     DOI： 10.1056/NEJMp1512750

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

1.  Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.

Authors:  James I Barnes; Vasu Divi; Adrian Begaye; Russell Wong; Steven Coutre; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  Blood Adv       Date:  2018-08-14

Review 2.  The Value of Medicines: A Crucial but Vague Concept.

Authors:  Fernando Antoñanzas; Robert Terkola; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

Review 3.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.

Authors:  S Vincent Rajkumar; Jean Luc Harousseau
Journal:  Blood       Date:  2016-10-14       Impact factor: 22.113

4.  Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies.

Authors:  Aris Angelis; Huseyin Naci; Allan Hackshaw
Journal:  Pharmacoeconomics       Date:  2020-12       Impact factor: 4.981

5.  The Influence of Varying Cost Formats on Preferences.

Authors:  Charles Changchuan Jiang; Liana Fraenkel
Journal:  Med Decis Making       Date:  2016-11-17       Impact factor: 2.583

6.  Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

Authors:  Qiushi Chen; Nitin Jain; Turgay Ayer; William G Wierda; Christopher R Flowers; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; Jagpreet Chhatwal
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

7.  Coverage of New Drugs in Medicare Part D.

Authors:  Huseyin Naci; Ilias Kyriopoulos; William B Feldman; Thomas J Hwang; Aaron S Kesselheim; Amitabh Chandra
Journal:  Milbank Q       Date:  2022-05-03       Impact factor: 6.237

Review 8.  Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.

Authors:  David Beran; Margaret Ewen; Kasia Lipska; Irl B Hirsch; John S Yudkin
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

9.  Application of the Price-Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy.

Authors:  Andrea Messori
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

10.  Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.

Authors:  Alexander T Sandhu; Paul A Heidenreich; John Lin; Justin Parizo; Jay Bhattacharya; Jeremy D Goldhaber-Fiebert
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2022-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.